Our BioScience business is a leader in recombinant and plasma-based protein replacement therapies to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products and developmental technology used in adult stem-cell therapies; and vaccines.
Our Medical Products business manufactures products used in the delivery of fluids and drugs to patients. These include intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps, and inhalation anesthetics, as well as products and services related to pharmacy compounding, drug formulation and packaging technologies. The business also is a leading provider of products and services for peritoneal dialysis, a home-based therapy for people with end-stage kidney disease, and other products used in dialysis therapy. Sales from businesses within Medical Products were $7.2 billion in 2010 and represented approximately 56 percent of Baxter's annual sales.